,3 The increasing prevalence of obesity and its status as a chronic disease4 underscores the importance of developing new therapeutic approaches, such as the long-acting human amylin analogue cagrilintide, which is currently under clinical development in combination with semaglutide for obesity and T2D.5 The gene discussed is IAPP; the disease is obesity due to melanocortin 4 receptor deficiency.